HRP20220053T1 - Farmaceutski sastavi koji sadrže rpl554 u hfa-134a za primjenu inhalacijom - Google Patents
Farmaceutski sastavi koji sadrže rpl554 u hfa-134a za primjenu inhalacijom Download PDFInfo
- Publication number
- HRP20220053T1 HRP20220053T1 HRP20220053TT HRP20220053T HRP20220053T1 HR P20220053 T1 HRP20220053 T1 HR P20220053T1 HR P20220053T T HRP20220053T T HR P20220053TT HR P20220053 T HRP20220053 T HR P20220053T HR P20220053 T1 HRP20220053 T1 HR P20220053T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical composition
- liquid pharmaceutical
- use according
- rpl554
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1816447.5A GB2578093B (en) | 2018-10-09 | 2018-10-09 | Liquid pharmaceutical composition comprising RPL554 and HFA-134A |
| EP19790718.1A EP3820446B1 (en) | 2018-10-09 | 2019-10-09 | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation |
| PCT/GB2019/052863 WO2020074894A1 (en) | 2018-10-09 | 2019-10-09 | Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220053T1 true HRP20220053T1 (hr) | 2022-04-15 |
Family
ID=64394831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220053TT HRP20220053T1 (hr) | 2018-10-09 | 2019-10-09 | Farmaceutski sastavi koji sadrže rpl554 u hfa-134a za primjenu inhalacijom |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20210379053A1 (enExample) |
| EP (2) | EP3960157A1 (enExample) |
| JP (2) | JP7578587B2 (enExample) |
| KR (1) | KR20210073532A (enExample) |
| CN (1) | CN112912064B (enExample) |
| AU (1) | AU2019358585B2 (enExample) |
| BR (1) | BR112021006712A2 (enExample) |
| CA (1) | CA3113167A1 (enExample) |
| CY (1) | CY1124943T1 (enExample) |
| DK (1) | DK3820446T3 (enExample) |
| ES (1) | ES2899744T3 (enExample) |
| GB (1) | GB2578093B (enExample) |
| HR (1) | HRP20220053T1 (enExample) |
| HU (1) | HUE057780T2 (enExample) |
| IL (1) | IL282032A (enExample) |
| LT (1) | LT3820446T (enExample) |
| MX (2) | MX2021003599A (enExample) |
| MY (1) | MY207302A (enExample) |
| PH (1) | PH12021550767A1 (enExample) |
| PL (1) | PL3820446T3 (enExample) |
| PT (1) | PT3820446T (enExample) |
| RS (1) | RS62775B1 (enExample) |
| SG (1) | SG11202102567UA (enExample) |
| SI (1) | SI3820446T1 (enExample) |
| SM (1) | SMT202200044T1 (enExample) |
| WO (1) | WO2020074894A1 (enExample) |
| ZA (1) | ZA202102039B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3231444T1 (sl) | 2014-05-12 | 2020-04-30 | Verona Pharma Plc | Novo zdravljenje |
| GB201502260D0 (en) | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
| GB2594480A (en) * | 2020-04-28 | 2021-11-03 | Verona Pharma Plc | New treatment |
| GB202202297D0 (en) | 2022-02-21 | 2022-04-06 | Verona Pharma Plc | Formulation production process |
| JP2025534762A (ja) * | 2022-10-28 | 2025-10-17 | 江蘇恒瑞医薬股▲ふん▼有限公司 | イソキノリノン系化合物を含む医薬組成物及びその調製方法 |
| EP4378942A1 (en) | 2022-12-02 | 2024-06-05 | Sandoz AG | Crystal form of a pde3/4 inhibitor |
| TW202506117A (zh) | 2023-06-26 | 2025-02-16 | 英商維羅納製藥Ｐｌｃ公司 | 顆粒組成物 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1165558B1 (en) | 1999-03-31 | 2003-09-24 | Vernalis Limited | Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| PH12013500261A1 (en) * | 2010-08-09 | 2013-03-04 | Verona Pharma Plc | Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound |
| US10022303B2 (en) * | 2012-02-28 | 2018-07-17 | Iceutica Pty Ltd. | Inhalable pharmaceutical compositions |
| PT2968313T (pt) * | 2013-03-15 | 2018-02-21 | Verona Pharma Plc | Combinação de fármacos |
| SI3231444T1 (sl) * | 2014-05-12 | 2020-04-30 | Verona Pharma Plc | Novo zdravljenje |
| DK3494962T3 (da) * | 2014-09-15 | 2021-06-21 | Verona Pharma Plc | Flydende inhalationsformulering omfattende RPL554 |
| GB201502260D0 (en) * | 2015-02-11 | 2015-04-01 | Verona Pharma Plc | Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound |
-
2018
- 2018-10-09 GB GB1816447.5A patent/GB2578093B/en active Active
-
2019
- 2019-10-09 JP JP2021517866A patent/JP7578587B2/ja active Active
- 2019-10-09 MX MX2021003599A patent/MX2021003599A/es unknown
- 2019-10-09 ES ES19790718T patent/ES2899744T3/es active Active
- 2019-10-09 DK DK19790718.1T patent/DK3820446T3/da active
- 2019-10-09 US US17/280,452 patent/US20210379053A1/en not_active Abandoned
- 2019-10-09 EP EP21198029.7A patent/EP3960157A1/en active Pending
- 2019-10-09 KR KR1020217010706A patent/KR20210073532A/ko not_active Ceased
- 2019-10-09 SI SI201930145T patent/SI3820446T1/sl unknown
- 2019-10-09 LT LTEPPCT/GB2019/052863T patent/LT3820446T/lt unknown
- 2019-10-09 HR HRP20220053TT patent/HRP20220053T1/hr unknown
- 2019-10-09 AU AU2019358585A patent/AU2019358585B2/en active Active
- 2019-10-09 WO PCT/GB2019/052863 patent/WO2020074894A1/en not_active Ceased
- 2019-10-09 PT PT197907181T patent/PT3820446T/pt unknown
- 2019-10-09 CN CN201980065895.8A patent/CN112912064B/zh active Active
- 2019-10-09 SG SG11202102567UA patent/SG11202102567UA/en unknown
- 2019-10-09 HU HUE19790718A patent/HUE057780T2/hu unknown
- 2019-10-09 MY MYPI2021001479A patent/MY207302A/en unknown
- 2019-10-09 CA CA3113167A patent/CA3113167A1/en active Pending
- 2019-10-09 SM SM20220044T patent/SMT202200044T1/it unknown
- 2019-10-09 RS RS20211599A patent/RS62775B1/sr unknown
- 2019-10-09 BR BR112021006712-4A patent/BR112021006712A2/pt unknown
- 2019-10-09 EP EP19790718.1A patent/EP3820446B1/en active Active
- 2019-10-09 PL PL19790718T patent/PL3820446T3/pl unknown
-
2021
- 2021-03-25 ZA ZA2021/02039A patent/ZA202102039B/en unknown
- 2021-03-26 MX MX2024001499A patent/MX2024001499A/es unknown
- 2021-04-04 IL IL282032A patent/IL282032A/en unknown
- 2021-04-06 PH PH12021550767A patent/PH12021550767A1/en unknown
-
2022
- 2022-02-02 CY CY20221100086T patent/CY1124943T1/el unknown
-
2024
- 2024-03-26 US US18/616,878 patent/US20250049781A1/en active Pending
- 2024-06-05 JP JP2024091837A patent/JP2024113096A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220053T1 (hr) | Farmaceutski sastavi koji sadrže rpl554 u hfa-134a za primjenu inhalacijom | |
| Carrigy et al. | Anti-tuberculosis bacteriophage D29 delivery with a vibrating mesh nebulizer, jet nebulizer, and soft mist inhaler | |
| JP2024113096A5 (enExample) | ||
| HRP20211035T1 (hr) | Tekuća formulacija za inhalaciju koja sadrži rpl554 | |
| UA107499C2 (uk) | Склад сухого порошку, який містить антимускариновий засіб | |
| HRP20151214T4 (hr) | Pripravak za inhalaciju koji sadrži aklidinij za liječenje kronične opstruktivne plućne bolesti | |
| JP2016534142A5 (enExample) | ||
| EA201591869A1 (ru) | Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой | |
| UY34838A (es) | Nueva forma de dosificación y formulación | |
| HRP20230147T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| JP2015519356A5 (enExample) | ||
| MX2017004476A (es) | Composicion que comprende al menos un polvo seco obtenido por secado por atomizacion para aumentar la estabilidad de la formulacion. | |
| HUE030983T2 (en) | Inhalable medicine containing thiotropium | |
| WO2017069721A1 (en) | Antiviral pharmaceutical composition | |
| JP2008540506A5 (enExample) | ||
| JP5938476B2 (ja) | 呼吸器疾患を治療するための定量噴霧式吸入剤を調製する方法 | |
| HRP20160630T1 (hr) | Farmaceutske aerosolne formulacije formoterola i beklometazon-dipropionata | |
| EP2821061B1 (en) | Novel inhalation formulations | |
| MY187442A (en) | A pharmaceutical composition containing budesonide and formoterol | |
| RU2013148786A (ru) | Улучшенный состав суспензии кортикостероида для ингаляционного введения | |
| CA2930173A1 (en) | An inhalable medicament | |
| Das et al. | Understanding the Respiratory Delivery of High Dose Anti‐Tubercular Drugs | |
| WO2023177366A1 (en) | Use of active ingredient used against viral diseases with pressurized metered dose inhaler in the treatment of covid-19 and other viral lung diseases | |
| MX372705B (es) | Composición farmacéutica que contiene budesonida y formoterol | |
| JP2011509936A5 (enExample) |